{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:30Z","timestamp":1792784910953,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"UK Research and Innovation Knowledge Transfer Partnership","id":[{"id":"https:\/\/ror.org\/001aqnf71","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Effective, non-invasive treatments for motor and non-motor symptoms in Parkinson\u2019s disease (PD) remain limited, and wearable vibrotactile stimulation may help by enhancing sensorimotor integration. This multi-centre, double-blind, pilot randomised controlled trial evaluated the usability, safety and tolerability of the CUE1+ sternum-worn vibrotactile device, with exploratory clinical outcomes compared with a sham device. Fifty adults with idiopathic PD, stable on antiparkinsonian medication, were randomised to active CUE1+ (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200925) or sham (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200925) for 12-weeks (8\u2009h\/day), with ON-medication assessments at baseline and week-13. Four participants (8%) discontinued; compliance exceeded 95% in both groups, and 2 (4.2%) experienced mild, transient skin irritation. Exploratory between-group differences favoured active stimulation on MDS-UPDRS Part III (\u221211.1 points; 95%CI \u221217.3 to \u22124.9) and the PDQ-39 Summary Index (\u22127.6 points; 95%CI \u221212.3 to \u22123.0). CUE1+ was usable, safe, and well tolerated. The exploratory clinical signals do not establish efficacy and require confirmation in adequately powered trials using an active vibrotactile sham. Trial registration: ClinicalTrials.gov, NCT06174948. Registered 13 February 2024.\n                  <\/jats:p>","DOI":"10.1038\/s41531-026-01448-y","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:25:14Z","timestamp":1783113914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sternum-worn vibrotactile device in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled pilot trial"],"prefix":"10.1038","volume":"12","author":[{"given":"Viktoria","family":"Azoidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essa","family":"Bhadra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Camboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamalesh C.","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Zirra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Rowsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrine","family":"Quah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Budu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Bestwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair J.","family":"Noyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Simonet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"1448_CR1","first-page":"165","volume":"78","author":"VL Feigin","year":"2021","unstructured":"Feigin, V. L. et al. GBD 2017 US Neurological Disorders Collaborators. Burden of neurological disorders across the US from 1990 to 2017: a Global Burden of Disease study. JAMA Neurol 78, 165\u2013176 (2021).","journal-title":"Burden of neurological disorders across the US from 1990 to 2017: a Global Burden of Disease study. JAMA Neurol"},{"key":"1448_CR2","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem, B. R., Okun, M. S. & Klein, C. Parkinson\u2019s disease. Lancet 397, 2284\u20132303 (2021).","journal-title":"Lancet"},{"key":"1448_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","volume":"75","author":"ER Dorsey","year":"2018","unstructured":"Dorsey, E. R. & Bloem, B. R. The Parkinson pandemic: a call to action. JAMA Neurol 75, 9\u201310 (2018).","journal-title":"JAMA Neurol"},{"key":"1448_CR4","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"1448_CR5","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/mds.27195","volume":"32","author":"A Fasano","year":"2017","unstructured":"Fasano, A., Canning, C. G., Hausdorff, J. M., Lord, S. & Rochester, L. Falls in Parkinson\u2019s disease: a complex and evolving picture. Mov. Disord. 32, 1524\u20131536 (2017).","journal-title":"Mov. Disord."},{"key":"1448_CR6","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn, S. et al. Levodopa and the progression of Parkinson\u2019s disease. N. Engl. J. Med. 351, 2498\u20132508 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1448_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa060281","volume":"355","author":"G Deuschl","year":"2006","unstructured":"Deuschl, G. et al. A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. N. Engl. J. Med. 355, 896\u2013908 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1448_CR8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"CW Olanow","year":"2006","unstructured":"Olanow, C. W., Obeso, J. A. & Stocchi, F. Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol 5, 677\u2013687 (2006).","journal-title":"Lancet Neurol"},{"key":"1448_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/NDT.S273121","volume":"19","author":"N Masood","year":"2023","unstructured":"Masood, N. & Jimenez-Shahed, J. Effective management of \u201cOFF\u201d episodes in Parkinson\u2019s disease: emerging treatment strategies and unmet clinical needs. Neuropsychiatr. Dis. Treat. 19, 247\u2013266 (2023).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"1448_CR10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMct1208070","volume":"367","author":"MS Okun","year":"2012","unstructured":"Okun, M. S. Deep-brain stimulation for Parkinson\u2019s disease. N. Engl. J. Med. 367, 1529\u20131538 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1448_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41582-018-0128-2","volume":"15","author":"AM Lozano","year":"2019","unstructured":"Lozano, A. M. et al. Deep brain stimulation: current challenges and future directions. Nat. Rev. Neurol. 15, 148\u2013160 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"1448_CR12","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S1353-8020(13)70013-0","volume":"20","author":"S Little","year":"2014","unstructured":"Little, S. & Brown, P. The functional role of beta oscillations in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 20, S44\u2013S48 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1448_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1136\/jnnp.69.3.308","volume":"69","author":"A Schrag","year":"2000","unstructured":"Schrag, A., Jahanshahi, M. & Quinn, N. What contributes to quality of life in patients with Parkinson\u2019s disease? J. Neurol. Neurosurg. Psychiatry 69, 308\u2013312 (2000).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1448_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/mds.23961","volume":"27","author":"C Hinnell","year":"2012","unstructured":"Hinnell, C. et al. Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson\u2019s disease? Mov. Disord. 27, 236\u2013241 (2012).","journal-title":"Mov. Disord."},{"key":"1448_CR15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.apmr.2012.10.026","volume":"94","author":"SJ Spaulding","year":"2013","unstructured":"Spaulding, S. J. et al. Cueing and gait improvement among people with Parkinson\u2019s disease: a meta-analysis. Arch. Phys. Med. Rehabil. 94, 562\u2013570 (2013).","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"1448_CR16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/jamaneurol.2019.0033","volume":"76","author":"J Nonnekes","year":"2019","unstructured":"Nonnekes, J. et al. Compensation strategies for gait impairments in Parkinson disease: a review. JAMA Neurol. 76, 718\u2013725 (2019).","journal-title":"JAMA Neurol."},{"key":"1448_CR17","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/S1353-8020(09)70781-3","volume":"15","author":"A Nieuwboer","year":"2009","unstructured":"Nieuwboer, A., Rochester, L., M\u00fcncks, L. & Swinnen, S. P. Motor learning in Parkinson\u2019s disease: limitations and potential for rehabilitation. Parkinsonism Relat. Disord. 15, S53\u2013S58 (2009).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1448_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.brainres.2010.01.001","volume":"1319","author":"L Rochester","year":"2010","unstructured":"Rochester, L. et al. Evidence for motor learning in Parkinson\u2019s disease: acquisition, automaticity and retention of cued gait performance after training with external rhythmical cues. Brain Res. 1319, 103\u2013111 (2010).","journal-title":"Brain Res."},{"key":"1448_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ana.26306","volume":"91","author":"A Tosserams","year":"2022","unstructured":"Tosserams, A. et al. Cortical correlates of gait compensation strategies in Parkinson disease. Ann. Neurol. 91, 329\u2013341 (2022).","journal-title":"Ann. Neurol."},{"key":"1448_CR20","doi-asserted-by":"publisher","first-page":"e38498","DOI":"10.1371\/journal.pone.0038498","volume":"7","author":"Y Sawada","year":"2012","unstructured":"Sawada, Y. et al. Attentional set-shifting deficit in Parkinson\u2019s disease is associated with prefrontal dysfunction: an FDG-PET study. PLoS One 7, e38498 (2012).","journal-title":"PLoS One"},{"key":"1448_CR21","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1007\/s00415-023-11663-9","volume":"270","author":"EC Klaver","year":"2023","unstructured":"Klaver, E. C. et al. Good vibrations: tactile cueing for freezing of gait in Parkinson\u2019s disease. J. Neurol. 270, 3424\u20133432 (2023).","journal-title":"J. Neurol."},{"key":"1448_CR22","doi-asserted-by":"publisher","first-page":"105189","DOI":"10.1016\/j.neubiorev.2023.105189","volume":"150","author":"C Cosentino","year":"2023","unstructured":"Cosentino, C. et al. One cue does not fit all: a systematic review with meta-analysis of the effectiveness of cueing on freezing of gait in Parkinson\u2019s disease. Neurosci. Biobehav. Rev. 150, 105189 (2023).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1448_CR23","doi-asserted-by":"publisher","first-page":"100284","DOI":"10.1016\/j.prdoa.2024.100284","volume":"11","author":"V Azoidou","year":"2024","unstructured":"Azoidou, V., Noyce, A. J. & Simonet, C. The effect of tactile cueing on dual task performance in Parkinson\u2019s disease: a systematic review and meta-analysis. Clin. Parkinsonism Relat. Disord. 11, 100284 (2024).","journal-title":"Clin. Parkinsonism Relat. Disord."},{"key":"1448_CR24","doi-asserted-by":"publisher","first-page":"107349","DOI":"10.1016\/j.parkreldis.2025.107349","volume":"133","author":"V Azoidou","year":"2025","unstructured":"Azoidou, V. et al. A pilot interventional study on feasibility and effectiveness of the CUE1 device in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 133, 107349 (2025).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1448_CR25","first-page":"100379","volume":"13","author":"V Azoidou","year":"2025","unstructured":"Azoidou, V. et al. Usability, safety and tolerability of CUE1 vibrotactile device as promising therapeutic approach in orthostatic tremor. Clin. Park. Relat. Disord. 13, 100379 (2025).","journal-title":"Clin. Park. Relat. Disord."},{"key":"1448_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. Neurology 17, 427\u2013442 (1967).","journal-title":"Neurology"},{"key":"1448_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/JPD-2012-11071","volume":"2","author":"RI Griffiths","year":"2012","unstructured":"Griffiths, R. I. et al. Automated assessment of bradykinesia and dyskinesia in Parkinson\u2019s disease. J. Parkinsons Dis. 2, 47\u201355 (2012).","journal-title":"J. Parkinsons Dis."},{"key":"1448_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.7326\/M17-1028","volume":"167","author":"DB Taichman","year":"2017","unstructured":"Taichman, D. B. et al. Data sharing statements for clinical trials. Ann. Intern. Med. 167, 63\u201365 (2017).","journal-title":"Ann. Intern. Med."},{"key":"1448_CR29","doi-asserted-by":"publisher","first-page":"912730","DOI":"10.3389\/fnhum.2022.912730","volume":"16","author":"A Ramirez-Zamora","year":"2022","unstructured":"Ramirez-Zamora, A. et al. Editorial: deep brain stimulation think tank. Front. Hum. Neurosci. 16, 912730 (2022).","journal-title":"Front. Hum. Neurosci."},{"key":"1448_CR30","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.neuron.2013.01.020","volume":"77","author":"AM Lozano","year":"2013","unstructured":"Lozano, A. M. & Lipsman, N. Probing and regulating dysfunctional circuits using deep brain stimulation. Neuron 77, 406\u2013424 (2013).","journal-title":"Neuron"},{"key":"1448_CR31","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3390\/biomedicines14030532","volume":"14","author":"A Reyhanli","year":"2026","unstructured":"Reyhanli, A. et al. Reconsidering placebo effects in neuromodulation for Parkinson\u2019s disease: lessons for clinical trials and therapeutic translation. Biomedicines 14, 532 (2026).","journal-title":"Biomedicines"},{"key":"1448_CR32","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1007\/s00415-024-12529-4","volume":"271","author":"S Haji","year":"2024","unstructured":"Haji, S. et al. Factors associated with a placebo effect in Parkinson\u2019s disease in clinical trials: a meta-analysis. J. Neurol. 271, 5825\u20135837 (2024).","journal-title":"J. Neurol."},{"key":"1448_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/NPT.0000000000000286","volume":"44","author":"S Stuart","year":"2020","unstructured":"Stuart, S. & Mancini, M. Prefrontal cortical activation with open and closed-loop tactile cueing when walking and turning in Parkinson disease. J. Neurol. Phys. Ther. 44, 121\u2013131 (2020).","journal-title":"J. Neurol. Phys. Ther."},{"key":"1448_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.clinph.2025.02.255","volume":"172","author":"F Goltz","year":"2025","unstructured":"Goltz, F. et al. A prospective controlled study of a wearable rhythmic vibrotactile device for tremor in Parkinson\u2019s disease. Clin. Neurophysiol. 172, 51\u201360 (2025).","journal-title":"Clin. Neurophysiol."},{"key":"1448_CR35","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3233\/JPD-202247","volume":"10","author":"S Schootemeijer","year":"2020","unstructured":"Schootemeijer, S. et al. Barriers and motivators to engage in exercise for persons with Parkinson\u2019s disease. J. Parkinsons Dis. 10, 1293\u20131299 (2020).","journal-title":"J. Parkinsons Dis."},{"key":"1448_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112065","volume":"9","author":"D Volpe","year":"2014","unstructured":"Volpe, D., Giantin, M. G. & Fasano, A. A wearable proprioceptive stabilizer (Equistasi\u00ae) for rehabilitation of postural instability in Parkinson\u2019s disease. PLoS One 9, e112065 (2014).","journal-title":"PLoS One"},{"key":"1448_CR37","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3389\/fneur.2019.00998","volume":"10","author":"A Peppe","year":"2019","unstructured":"Peppe, A. et al. Proprioceptive focal stimulation (Equistasi\u00ae) may improve the quality of gait in Parkinson\u2019s disease. Front. Neurol. 10, 998 (2019).","journal-title":"Front. Neurol."},{"key":"1448_CR38","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/s19092101","volume":"19","author":"F Serio","year":"2019","unstructured":"Serio, F. et al. Focal vibration training (Equistasi\u00ae) to improve posture stability in Parkinson\u2019s disease. Sensors (Basel) 19, 2101 (2019).","journal-title":"Sensors (Basel)"},{"key":"1448_CR39","doi-asserted-by":"publisher","first-page":"106676","DOI":"10.1016\/j.clinbiomech.2025.106676","volume":"130","author":"SM Tiell","year":"2025","unstructured":"Tiell, S. M. & Davis, B. L. A literature review on vibrotactile stimulation devices for individuals with Parkinson\u2019s disease. Clin. Biomech. 130, 106676 (2025).","journal-title":"Clin. Biomech."},{"key":"1448_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","volume":"27","author":"H Hurst","year":"2004","unstructured":"Hurst, H. & Bolton, J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J. Manipulative Physiol. Ther. 27, 26\u201335 (2004).","journal-title":"J. Manipulative Physiol. Ther."},{"key":"1448_CR41","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1002\/mds.25079","volume":"27","author":"F Maier","year":"2012","unstructured":"Maier, F. et al. Impaired self-awareness of motor deficits in Parkinson\u2019s disease. Mov. Disord. 27, 1443\u20131447 (2012).","journal-title":"Mov. Disord."},{"key":"1448_CR42","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/mds.20935","volume":"21","author":"R Mercado","year":"2006","unstructured":"Mercado, R. et al. Expectation and the placebo effect in Parkinson\u2019s disease patients with subthalamic nucleus deep brain stimulation. Mov. Disord. 21, 1457\u20131461 (2006).","journal-title":"Mov. Disord."},{"key":"1448_CR43","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond, A. S. & Snaith, R. P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67, 361\u2013370 (1983).","journal-title":"Acta Psychiatr. Scand."},{"key":"1448_CR44","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp, L. B., LaRocca, N. G., Muir-Nash, J. & Steinberg, A. D. The fatigue severity scale. Arch. Neurol. 46, 1121\u20131123 (1989).","journal-title":"Arch. Neurol."},{"key":"1448_CR45","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse, D. J. et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 28, 193\u2013213 (1989).","journal-title":"Psychiatry Res."},{"key":"1448_CR46","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1212\/CPJ.0000000000000921","volume":"11","author":"MJ Armstrong","year":"2021","unstructured":"Armstrong, M. J., Rastgardani, T., Gagliardi, A. R. & Marras, C. Impact of OFF periods on persons with Parkinson disease and care partners. Neurol. Clin. Pract. 11, e232\u2013e238 (2021).","journal-title":"Neurol. Clin. Pract."},{"key":"1448_CR47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41531-025-01031-x","volume":"11","author":"A Zirra","year":"2025","unstructured":"Zirra, A. et al. The East London Parkinson\u2019s disease project. npj Parkinsons Dis 11, 172 (2025).","journal-title":"npj Parkinsons Dis"},{"key":"1448_CR48","doi-asserted-by":"publisher","first-page":"e096051","DOI":"10.1136\/bmjopen-2024-096051","volume":"15","author":"V Azoidou","year":"2025","unstructured":"Azoidou, V. et al. Non-invasive device to alleviate symptoms in people living with Parkinson\u2019s: study protocol for a multicentre phase II double-blind randomised controlled trial. BMJ Open 15, e096051 (2025).","journal-title":"BMJ Open"},{"key":"1448_CR49","doi-asserted-by":"publisher","DOI":"10.1177\/20552076211018617","volume":"7","author":"H Unsworth","year":"2021","unstructured":"Unsworth, H. et al. The NICE evidence standards framework for digital health and care technologies. Digit. Health 7, 20552076211018617 (2021).","journal-title":"Digit. Health"},{"key":"1448_CR50","unstructured":"National Health Service. Digital Health Evidence Generation Guide. (NHS England, 2023)."},{"key":"1448_CR51","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","volume":"73","author":"S Hoops","year":"2009","unstructured":"Hoops, S. et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73, 1738\u20131745 (2009).","journal-title":"Neurology"},{"key":"1448_CR52","unstructured":"Office for National Statistics. Ethnic group, England and Wales: Census 2021. https:\/\/www.ons.gov.uk (2021)."},{"key":"1448_CR53","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"1448_CR54","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1519\/JPT.0000000000000102","volume":"40","author":"C Petersen","year":"2017","unstructured":"Petersen, C. et al. Reliability and minimal detectable change for sit-to-stand tests and the Functional Gait Assessment for individuals with Parkinson disease. J. Geriatr. Phys. Ther. 40, 223\u2013226 (2017).","journal-title":"J. Geriatr. Phys. Ther."},{"key":"1448_CR55","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"39","author":"D Podsiadlo","year":"1991","unstructured":"Podsiadlo, D. & Richardson, S. The timed \u201cUp & Go\u201d: a test of basic functional mobility for frail elderly persons. J. Am. Geriatr. Soc. 39, 142\u2013148 (1991).","journal-title":"J. Am. Geriatr. Soc."},{"key":"1448_CR56","doi-asserted-by":"publisher","first-page":"e96260","DOI":"10.1371\/journal.pone.0096260","volume":"9","author":"AJ Noyce","year":"2014","unstructured":"Noyce, A. J. et al. Bradykinesia-akinesia incoordination test: validating an online keyboard test of upper limb function. PLoS One 9, e96260 (2014).","journal-title":"PLoS One"},{"key":"1448_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03563-7","volume":"12","author":"N Akram","year":"2022","unstructured":"Akram, N. et al. Developing and assessing a new web-based tapping test for measuring distal movement in Parkinson\u2019s disease. Sci. Rep. 12, 386 (2022).","journal-title":"Sci. Rep."},{"key":"1448_CR58","doi-asserted-by":"publisher","first-page":"M28","DOI":"10.1093\/gerona\/50A.1.M28","volume":"50A","author":"LE Powell","year":"1995","unstructured":"Powell, L. E. & Myers, A. M. The Activities-specific Balance Confidence (ABC) scale. J. Gerontol. A Biol. Sci. Med. Sci. 50A, M28\u2013M34 (1995).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"1448_CR59","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson, C. et al. The Parkinson\u2019s Disease Questionnaire (PDQ-39): development and validation. Age Ageing 26, 353\u2013357 (1997).","journal-title":"Age Ageing"},{"key":"1448_CR60","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jclinepi.2011.07.011","volume":"65","author":"J Sim","year":"2012","unstructured":"Sim, J. & Lewis, M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J. Clin. Epidemiol. 65, 301\u2013308 (2012).","journal-title":"J. Clin. Epidemiol."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01448-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01448-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01448-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:03:18Z","timestamp":1790262198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01448-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1448"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01448-y","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Charco Neurotech Ltd provided the CUE1+ and sham devices, adhesive patches, and covered costs associated with the Parkinson\u2019s KinetiGraph wristwatches used in this study. As pre-specified in the study protocol, all participants were offered a CUE1+ device and a three-month supply of adhesives from Charco Neurotech Ltd following trial completion. A.J.N. received a consultancy payment from Charco Neurotech Ltd for unrelated work more than four years prior to the initiation of any studies on this device at Queen Mary University of London. Within the past three years, A.J.N. has received research grants from Parkinson\u2019s UK, Barts Charity, Cure Parkinson\u2019s, the National Institute for Health and Care Research, Innovate UK, the Medical College of Saint Bartholomew\u2019s Hospital Trust, Alchemab, Aligning Science Across Parkinson\u2019s Global Parkinson\u2019s Genetics Program (ASAP-GP2), and the Michael J. Fox Foundation; and consultancy and\/or personal fees from AstraZeneca, AbbVie, Bial, Umedeor, Heptares, and Britannia. None of these relationships relates directly to the work reported here. No patents are pending in relation to this work. No author holds equity in, or has acted as a paid consultant for, Charco Neurotech Ltd in relation to this manuscript. The other authors do not have a competing interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"232"}}